Cancer Center Zürich First Zurich Immuno-Oncology Symposium Thursday, August 25th, 2016 09.15 – 17.00 h Grosser Hörsaal Ost UniversityHospital Zurich Welcome Dear colleagues Immunotherapy with immune checkpoint inhibitors has become a reality for patients with metastatic melanoma and patients with advanced non-small cell lung cancer with progressive disease after first line chemotherapy. Available data indicate patients with many other malignant diseases are likely to benefit from this form of therapy. The advent of immunotherapy brings new opportunities, but also new challenges to physicians advising patients and treating patients. We invite you to take part in the First Zurich Immuno-Oncology Symposium of the Cancer Center Zürich to familiarize yourself with the new developments. Liebe Kolleginnen und Kollegen Die Immuntherapie mit Immune Checkpoint Inhibitoren ist für Patienten mit metastasiertem Melanom und Patienten mit fortgeschrittenem nichtkleinzelligem Bronchuskarzinom mit Krankheitsprogression nach einer ErstlinienChemotherapie Wirklichkeit geworden und weckt neue Hoffnungen für eine Vielzahl anderer maligner Erkrankungen. Das Aufkommen der Immuntherapie bringt für Ärzte, die Patienten beraten und behandeln, neue Aufgaben und Möglichkeiten. Mit dem ersten Zürcher Symposium für Immunonkologie des Cancer Center Zürich laden wir Sie ein, sich mit dem Gebiet der Immuntherapie bei malignen Erkrankungen vertraut zu machen. Prof. Dr. Rolf Stahel Chair Cancer Center Zürich Prof. Dr. Michael Weller Deputy Chair Cancer Center Zürich Program 09.15 h Welcome Chairs: Alessandra Curioni, Reinhard Dummer, Rolf Stahel, Michael Weller 09.30 h Essentials of tumour immunology and immunotherapies Tumour immunology, Maries van den Broek Immunomonitoring, Bernd Bodenmiller Immune checkpoints – general overview, Alessandra Curioni 11.00 h Break 11.15 h Clinical results, patient cases and future developments I Melanoma, Reinhard Dummer Lung cancer and thoracic cancer, Rolf Stahel 12.45 h Lunch 13.30 h Clinical results, patient cases and future developments II Hemato-Oncology, Stefan Balabanov Head and neck cancer, Tamara Rordorf Renal and bladder cancer, Frank Stenner 15.00 h Break 15.15 h Clinical results, patient cases and future developments III CNS tumours, Michael Weller GI and breast tumours, Bernhard Pestalozzi 16.15 h Management of toxicities Management of toxicities; Response assessment, Alessandra Curioni, Reinhard Dummer and team 16.45 h Radiotherapy Radiotherapy as immune response modifier, Matthias Guckenberger 17.00 h Wrap up and closure Chairs Information Organization UniversityHospital Zurich Cancer Center Zürich Prof. Dr. Rolf Stahel Chair Cancer Center Zürich Rämistrasse 100 8091 Zurich, Switzerland Credits 6 SGMO-Credits Speakers Stefan Balabanov, PD Dr. Dr. Department of Hematology, USZ Bernd Bodenmiller, Prof. Dr. Institute of Molecular Life Sciences, University of Zurich Alessandra Curioni, PD Dr. Department of Oncology, USZ Registration Until August 10th 2016 at www.tumorzentrum.usz.ch/ symp-immuno-2016 or [email protected] Registration free of charge Venue UniversityHospital Zurich Gloriastrasse 29 8091 Zurich Switzerland Grosser Hörsaal Ost, HOER B 10 Tram 10 from Zurich Main Station / from Zurich Airport to «ETH / Universitätsspital» Reinhard Dummer, Prof. Dr. Department of Dermatology, USZ 2 Std. 1 Std. 2 Std. Matthias Guckenberger, Prof. Dr. Department of Radiooncology, USZ HUK 2 Bernhard Pestalozzi, Prof. Dr. Department of Oncology, USZ GLO II Tamara Rordorf, Dr. Department of Oncology, USZ Rolf Stahel, Prof. Dr. Cancer Center Zürich, USZ 2 St Frank Stenner, PD Dr. Department of Oncology, University Hospital Basel Michael Weller, Prof. Dr. Department of Neurology, USZ Kindly supported by a Grant from , and 06.2016 Maries van den Broek, Prof. Dr. Institute of Experimental Immunology, University of Zurich
© Copyright 2024 ExpyDoc
